J
James H. Gerlach
Researcher at Queen's University
Publications - 20
Citations - 4939
James H. Gerlach is an academic researcher from Queen's University. The author has contributed to research in topics: Multiple drug resistance & Gene expression. The author has an hindex of 14, co-authored 20 publications receiving 4845 citations. Previous affiliations of James H. Gerlach include University of Arizona.
Papers
More filters
Journal Article
Homogeneously staining region in anthracycline-resistant HL-60/AR cells not associated with MDR1 amplification.
James E. Gervasoni,Robert N. Taub,Ming Tsung Yu,Dorothy Warburton,Marlene Sabbath,Stephanie Gilleran,Donald L. Coppock,John D'Alessandri,Sindu Krishna,Michelle Rosado,Michael Baker,Jose Lutzky,Eva R. Chanda,James H. Gerlach,Michael J. Pinkoski,Susan P.C. Cole,Alexander Hindenburg +16 more
TL;DR: Although the HL-60/AR cells possess the classical multidrug resistance phenotype and demonstrate a homogeneously staining region near the region of the MDR1 gene, their resistance is due to mechanisms other than those coded for by MDR 1.
Journal ArticleDOI
Topoisomerase II levels and drug response in small cell lung cancer
Barbara G. Campling,Kathy A. Baer,James H. Gerlach,Yuk-Miu Lam,Susan P.C. Cole,Shelagh E. L. Mirski +5 more
TL;DR: An inverse correlation between topo II alpha levels and resistance to all of the tested drugs, including several drugs which are not known to interact with topo III, is revealed.
Journal ArticleDOI
Tumourigenic multidrug-resistant HT1080 cells do not overexpress receptors for epidermal growth factor.
Marilyn L. Slovak,Shelagh E. L. Mirski,Susan P.C. Cole,James H. Gerlach,K. H. Yohem,J. M. Trent +5 more
TL;DR: Tumourigenic multidrug-resistant HT1080 cells do not overexpress receptors for epidermal growth factor as discussed by the authors, but do not over-express receptors for EGF.
Book ChapterDOI
2 – P-Glycoprotein and Resistance to Anticancer Drugs
Victor Ling,James H. Gerlach,Helen S.L. Chan,Paul S. Thorner,Jean Gariépy,Grace Bradley,Elias Georges +6 more
HT1080cells donotoverexpress receptors forepidermal growth factor
TL;DR: Prospective HSR near the normal cellular locus for EGFR on the short arm of chromosome 7 shows support for the idea that drug resistance and the loss of tumourigenicity should be regarded as two independent events.